Effect of a Complementary Food Supplement on Growth and Morbidity of Ghanaian Infants (TRIUMF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03181178 |
Recruitment Status :
Completed
First Posted : June 8, 2017
Last Update Posted : March 1, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Prevention of malnutrition in infants and children requires access and intake of nutritious food starting at birth with exclusive breastfeeding for the first 6 months of life, breastfeeding in combination with complementary foods from 6-24 months of age, access to clean drinking water and sanitation, access to preventive and curative health care (including prenatal).
In Ghana, the Demographic and Health Survey of 2014 reports rates of stunting, wasting and underweight in children aged 0-59 months are 28%, 14% and 9% respectively. Furthermore, height for age starts dropping from age 4-6 months with children aged 6-23 months being more likely to be stunted (40%) than those below 6 months (4%). Infant and young child feeding data show that for breast-fed children ranging from 6 months through 35 months of age, cereals are predominantly the first foods introduced in the diet (6-8 months of age). As the child grows older, consumption of fruits rich in Vitamin A, other fruits and vegetables and meat, fish, poultry and eggs are reported by the mothers. The Demographic and Health Survey (DHS) found that the proportion of breast fed children aged 6-23 months who received a recommended variety of foods the minimum number of times per day increases with child's age from 28% in children 6-8 months to 50% in children aged 18-23 months.
The study objective is to examine the effect of providing a macro- and micro-nutrient fortified complementary food supplement (KokoPlusTM) on growth and nutritional status of Ghanaian infants.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Growth Disorders Infant Malnutrition Micronutrient Deficiency Protein Malnutrition Morbidity;Infant | Dietary Supplement: Macro-micronutrient complementary food supplement Dietary Supplement: A micronutrient powder Behavioral: Nutrition education | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1204 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The study has three intervention arms and one cross sectional growth monitoring follow up group. |
Masking: | Single (Participant) |
Masking Description: | Single blind cluster randomized trial - all participants in a community received the same treatment. |
Primary Purpose: | Prevention |
Official Title: | Effect of a Complementary Food Supplement on Growth and Morbidity of Ghanaian Infants (6 to 18 Months) |
Actual Study Start Date : | February 2013 |
Actual Primary Completion Date : | February 2015 |
Actual Study Completion Date : | February 2015 |

Arm | Intervention/treatment |
---|---|
Active Comparator: KokoPlus and Nutrition Education
Macro-micronutrient complementary food supplement and Nutrition Education
|
Dietary Supplement: Macro-micronutrient complementary food supplement
This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education Behavioral: Nutrition education This intervention provided nutrition education sessions |
Active Comparator: Micronutrient and Nutrition Education
A micronutrient powder and Nutrition Education
|
Dietary Supplement: A micronutrient powder
This intervention provided a 1 g micronutrient powder with nutrition education Behavioral: Nutrition education This intervention provided nutrition education sessions |
Active Comparator: Nutrition Education Only
Nutrition Education
|
Behavioral: Nutrition education
This intervention provided nutrition education sessions |
No Intervention: Growth Monitoring Only
Growth monitoring
|
- Change in monthly length for age Z-score (monthly LAZ) [ Time Frame: Measured on a monthly basis until 18 months of age ]Change in length for age Z-score from 6 months to 18 months of age.
- Change in Serum Hemoglobin [ Time Frame: Baseline (6 months), Midline (12 months of age), Endline (18 months of age) ]Change in serum hemoglobin from baseline to endline (6 months to 18 months)
- Change in Serum retinol binding protein [ Time Frame: Baseline (6 months), Midline (12 months of age), Endline (18 months of age) ]Change in serum retinol binding protein from baseline to endline (6 months to 18 months)
- Change in serum transferrin receptors [ Time Frame: Baseline (6 months), Midline (12 months of age), Endline (18 months of age) ]Change from baseline to endline (6 months to 18 months)
- Change in serum ferritin [ Time Frame: Baseline (6 months), Midline (12 months of age), Endline (18 months of age) ]Change from baseline to endline (6 months to 18 months)
- Change in serum zinc [ Time Frame: Baseline (6 months), Midline (12 months of age), Endline (18 months of age) ]Change from baseline to endline (6 months to 18 months)
- Change in Weight for age Z-score [ Time Frame: Measured at baseline and then on a monthly basis for the duration of the intervention (12 months) ]This is the change in weight for age Z-score from 6 months to 18 months of age
- Change in Weight for height Z-score [ Time Frame: Measured at baseline and then on a monthly basis for the duration of the intervention (12 months) ]This is the change in weight for length Z-score from 6 months to 18 months of age
- Prevalence of diarrhea [ Time Frame: Measured at baseline and then in a weekly surveillance for the duration of the intervention (12 months or 52 weeks) ]Prevalence of diarrhea over a 12 month period (duration of intervention)
- Prevalence of upper respiratory infections [ Time Frame: Measured at baseline and then in a weekly surveillance for the duration of the intervention (12 months or 52 weeks) ]Prevalence of respiratory infections over a 12 month period (duration of the intervention)
- Change in serum C-reactive protein [ Time Frame: Baseline (6 months), Midline (12 months of age), Endline (18 months of age) ]Change from baseline to endline (6 months to 18 months)
- Change in serum alpha glycoprotein [ Time Frame: Baseline (6 months), Midline (12 months of age), Endline (18 months of age) ]Change from baseline to endline (6 months to 18 months)
- Change in Head Circumference for age [ Time Frame: Measured at baseline and then on a monthly basis for the duration of the intervention (12 months) ]This is the change in head circumference for age from 6 months to 18 months of
- Change in MUAC (Mid Upper Arm Circumference) [ Time Frame: Measured at baseline and then on a monthly basis for the duration of the intervention (12 months) ]This is the change in MUAC for age from 6 months to 18 months of age
- Change in Plasma Amino Acid levels [ Time Frame: Baseline (6 months), Midline (12 months of age), Endline (18 months of age) ]This is the change in individual plasma amino acids from 6 months to 18 months

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Months to 6 Months (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Non pre-term
- Singleton birth
- Exclusively or predominantly breast fed up to time of recruitment
- Parents planning to live in community for a period of 12 months and willing to participate in the trial for the entire period
- Receive informed consent from both parents and/or caregivers or from mother alone if single
Exclusion Criteria:
- Severely anemic (<7 g/dl) (to be referred to Community Health Post (CHP) for routine care on anemia as recommended by Ghana Health Service)
- Severely malnourished (MUAC <110 mm) (to be referred to CHP with Community-based Management of Acute Malnutrition (CMAM) protocol) and/or use of CMAM protocol or below -2 standard deviations (SD) weight for age Z score

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03181178
Principal Investigator: | Shibani Ghosh, PhD | Nevin Scrimshaw International Nutrition Foundation | |
Principal Investigator: | Gloria Otoo, PhD | University of Ghana | |
Principal Investigator: | Kwaku Tano-Debrah, PhD | University of Ghana |
Responsible Party: | Shibani Ghosh, Senior Scientist, Nevin Scrimshaw International Nutrition Foundation |
ClinicalTrials.gov Identifier: | NCT03181178 |
Other Study ID Numbers: |
Ghana Trial |
First Posted: | June 8, 2017 Key Record Dates |
Last Update Posted: | March 1, 2018 |
Last Verified: | February 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There is no plan to share individual participant data to other researchers |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Complementary food supplement Protein quality and linear growth Intervention targeting complementary foods and growth |
Malnutrition Infant Nutrition Disorders Kwashiorkor Growth Disorders Nutrition Disorders Pathologic Processes |
Severe Acute Malnutrition Micronutrients Trace Elements Nutrients Growth Substances Physiological Effects of Drugs |